1. Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase
    Bhupinder Kumar et al, 2019, European Journal of Medicinal Chemistry CrossRef
  2. Newly Developed Drugs for Alzheimer’s Disease in Relation to Energy Metabolism, Cholinergic and Monoaminergic Neurotransmission
    Jan Korábečný et al, 2018, Neuroscience CrossRef
  3. Design, Synthesis and Evaluation of O ‐Pentyne Substituted Diphenylpyrimidines as Monoamine Oxidase and Acetylcholinesterase Inhibitors
    Vijay Kumar et al, 2020, ChemistrySelect CrossRef
  4. Multitarget Biological Profiling of New Naphthoquinone and Anthraquinone-Based Derivatives for the Treatment of Alzheimer’s Disease
    Marta Campora et al, 2021, ACS Chemical Neuroscience CrossRef
  5. Recent Progress on Biological Activity of Amaryllidaceae and Further Isoquinoline Alkaloids in Connection with Alzheimer’s Disease
    Lucie Cahlíková et al, 2021, Molecules CrossRef
  6. Deciphering the detailed structure–activity relationship of coumarins as Monoamine oxidase enzyme inhibitors—An updated review
    Vishal Payyalot Koyiparambath et al, 2021, Chemical Biology & Drug Design CrossRef
  7. Receptor Targets in Alzheimer’s Disease Drug Discovery
    J. Wallach et al, 2017, Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders CrossRef
  8. Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson's disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies
    Ahmed Elkamhawy et al, 2021, Bioorganic Chemistry CrossRef
  9. Gamma-decanolactone: Preliminary evaluation as potential antiparkinsonian drug
    Pricila Pflüger et al, 2021, European Journal of Pharmacology CrossRef
  10. Utility of Reactive Species Generation in Plasma Medicine for Neuronal Development
    Sarmistha Mitra et al, 2020, Biomedicines CrossRef
  11. Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer’s Disease
    Edilio Borroni et al, 2017, Journal of Pharmacology and Experimental Therapeutics CrossRef
  12. Design, synthesis and biological evaluation of novel donepezil–coumarin hybrids as multi-target agents for the treatment of Alzheimer’s disease
    Sai-Sai Xie et al, 2016, Bioorganic & Medicinal Chemistry CrossRef
  13. The TLC-Bioautography as a Tool for Rapid Enzyme Inhibitors detection - A Review
    Barbora Legerská et al, 2020, Critical Reviews in Analytical Chemistry CrossRef
  14. Monoamine oxidase-B inhibitor protects degenerating spinal neurons, enhances nerve regeneration and functional recovery in sciatic nerve crush injury model
    Al-Shimali M. Hussain et al, 2018, Neuropharmacology CrossRef
  15. Progress in drug development for Alzheimer's disease: An overview in relation to mitochondrial energy metabolism
    Jana Hroudová et al, 2016, European Journal of Medicinal Chemistry CrossRef
  16. Rhizophora mucronata attenuates beta-amyloid induced cognitive dysfunction, oxidative stress and cholinergic deficit in Alzheimer’s disease animal model
    Natarajan Suganthy et al, 2016, Metabolic Brain Disease CrossRef
  17. Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease
    Qi Li et al, 2018, European Journal of Medicinal Chemistry CrossRef
  18. Alternative splicing in serotonergic system: Implications in neuropsychiatric disorders
    Eva Latorre et al, 2019, Journal of Psychopharmacology CrossRef
  19. Whether short peptides are good candidates for future neuroprotective therapeutics?
    Renata Perlikowska, 2021, Peptides CrossRef
  20. Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis
    Hyun-U Cho et al, 2021, Experimental & Molecular Medicine CrossRef
  21. The Reactive Species Interactome in the Brain
    Elise Malard et al, 2021, Antioxidants & Redox Signaling CrossRef
  22. Neuroprotective effects of the monoamine oxidase inhibitor tranylcypromine and its amide derivatives against Aβ(1–42)-induced toxicity
    Filippo Caraci et al, 2015, European Journal of Pharmacology CrossRef
  23. Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
    Stephan Schilling et al, 2018, Molecules CrossRef
  24. Multifunctional Ligands Targeting Phosphodiesterase as the Future Strategy for the Symptomatic and Disease-Modifying Treatment of Alzheimer’s Disease
    Agnieszka Jankowska et al, 2020, Current Medicinal Chemistry CrossRef
  25. N-Acetylcysteine and Safranal prevented the brain damage induced by hyperthyroidism in adult male rats
    Asmaa S. Shahat et al, 2020, Nutritional Neuroscience CrossRef
  26. Recent Updates in the Alzheimer’s Disease Etiopathology and Possible Treatment Approaches: A Narrative Review of Current Clinical Trials
    Elahe Zarini-Gakiye et al, 2020, Current Molecular Pharmacology CrossRef
  27. Acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease – a patent review (2016–present)
    Martina Bortolami et al, 2021, Expert Opinion on Therapeutic Patents CrossRef
  28. Flurbiprofen-chalcone hybrid Mannich base derivatives as balanced multifunctional agents against Alzheimer’s disease: Design, synthesis and biological evaluation
    Chaoquan Tian et al, 2020, Bioorganic Chemistry CrossRef
  29. New flavonoid – N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties
    Martín Estrada-Valencia et al, 2019, Journal of Enzyme Inhibition and Medicinal Chemistry CrossRef
  30. An investigation of the monoamine oxidase inhibition properties of pyrrolo[3,4-f]indole-5,7-dione and indole-5,6-dicarbonitrile derivatives
    Zhanna V. Chirkova et al, 2018, Drug Development Research CrossRef
  31. Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer's disease
    Tao Wang et al, 2019, European Journal of Medicinal Chemistry CrossRef
  32. DL -3- n -butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid- β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer’s therapy
    Xiaoming Qiang et al, 2017, Bioorganic & Medicinal Chemistry Letters CrossRef
  33. Inhibition of BACE1, MAO‐B, cholinesterase enzymes, and anti‐amyloidogenic potential of selected natural phytoconstituents: Multi‐target‐directed ligand approach
    Suman Chowdhury et al, 2021, Journal of Food Biochemistry CrossRef
  34. Role of Monoamine Oxidase Activity in Alzheimer’s Disease: An Insight into the Therapeutic Potential of Inhibitors
    Tapan Behl et al, 2021, Molecules CrossRef
  35. Progress in Target Drug Molecules for Alzheimer's Disease
    Jiayang Xie et al, 2020, Current Topics in Medicinal Chemistry CrossRef
  36. Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review
    Zahra Haghighijoo et al, 2022, European Journal of Medicinal Chemistry CrossRef
  37. Highly sensitive isotope-dilution liquid-chromatography–electrospray ionization–tandem-mass spectrometry approach to study the drug-mediated modulation of dopamine and serotonin levels in Caenorhabditis elegans
    Fabian Schumacher et al, 2015, Talanta CrossRef
  38. Design, synthesis and bioevalucation of novel 2,3-dihydro-1 H -inden-1-amine derivatives as potent and selective human monoamine oxidase B inhibitors based on rasagiline
    Xuan Xiao et al, 2018, European Journal of Medicinal Chemistry CrossRef
  39. A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer’s Disease
    Soo Youn Lee et al, 2020, Frontiers in Pharmacology CrossRef
  40. Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies
    Piyoosh Sharma et al, 2019, Progress in Neurobiology CrossRef
  41. Selective Interactions of O-Methylated Flavonoid Natural Products with Human Monoamine Oxidase-A and -B
    Narayan D. Chaurasiya et al, 2020, Molecules CrossRef
  42. Synthesis, biological evaluation, and molecular modeling of nitrile‐containing compounds: Exploring multiple activities as anti‐Alzheimer agents
    Daniel Silva et al, 2020, Drug Development Research CrossRef
  43. Pharmacological investigations on efficacy of Phlorizin a sodium-glucose co-transporter (SGLT) inhibitor in mouse model of intracerebroventricular streptozotocin induced dementia of AD type
    Reena Rani et al, 2021, Journal of Basic and Clinical Physiology and Pharmacology CrossRef
  44. Effects of novel 17β-hydroxysteroid dehydrogenase type 10 inhibitors on mitochondrial respiration
    Zdeněk Fišar et al, 2021, Toxicology Letters CrossRef
  45. Identification of phytochemicals from North African plants for treating Alzheimer’s diseases and of their molecular targets by in silico network pharmacology approach
    Karim Raafat, 2021, Journal of Traditional and Complementary Medicine CrossRef
  46. Protective effect of paeoniflorin on inflammation and apoptosis in the cerebral cortex of a transgenic mouse model of Alzheimer's disease
    XINYI GU et al, 2016, Molecular Medicine Reports CrossRef
  47. Monoamine oxidases in age-associated diseases: New perspectives for old enzymes
    Yohan Santin et al, 2021, Ageing Research Reviews CrossRef
  48. Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework
    Anton Shetnev et al, 2019, Bioorganic & Medicinal Chemistry Letters CrossRef
  49. Regulation | Monoamine Oxidases
    Sudhir Raghavan et al, 2021, Encyclopedia of Biological Chemistry III CrossRef
  50. Effects of different fatty acids composition of phosphatidylcholine on brain function of dementia mice induced by scopolamine
    Miao-miao Zhou et al, 2016, Lipids in Health and Disease CrossRef
  51. Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches
    Pablo Duarte et al, 2020, Reactive Oxygen Species CrossRef
  52. Metabolic depletion of synaptosomal enzymes linked with neurotoxicity and ovarian dysfunction by phenolic antioxidants of Croton zambsicus leaves in rats exposed to chronic mixture of anthropogenic toxicant
    J.K. Akintunde et al, 2021, Metabolism Open CrossRef
  53. Identification of AV-1451 as a Weak, Nonselective Inhibitor of Monoamine Oxidase
    Lindsey R. Drake et al, 2019, ACS Chemical Neuroscience CrossRef
  54. Egg yolk phospholipids reverse scopolamine–induced spatial memory deficits in mice by attenuating cholinergic damage
    Zhijie Bao et al, 2020, Journal of Functional Foods CrossRef
  55. Antioxidant and Anti-Inflammatory Profiles of Spent Coffee Ground Extracts for the Treatment of Neurodegeneration
    Simone Angeloni et al, 2021, Oxidative Medicine and Cellular Longevity CrossRef
  56. Acetylcholinesterase and butyrylcholinesterase inhibitory activities of khellactone coumarin derivatives isolated from Peucedanum japonicum Thurnberg
    Jeong Hyun Heo et al, 2020, Scientific Reports CrossRef
  57. Critical evaluation of current Alzheimer’s drug discovery (2018–19) & futuristic Alzheimer drug model approach
    Atukuri Dorababu, 2019, Bioorganic Chemistry CrossRef
  58. Alkaloid extracts from shea butter and breadfruit as potential inhibitors of monoamine oxidase, cholinesterases, and lipid peroxidation in rats’ brain homogenates: a comparative study
    Stephen A. Adefegha et al, 2016, Comparative Clinical Pathology CrossRef
  59. Design, synthesis, and in vitro evaluation of 4-aminoalkyl-1(2H)-phthalazinones as potential multifunctional anti-Alzheimer’s disease agents
    Chanyuan Ye et al, 2021, Bioorganic Chemistry CrossRef
  60. Exploring the Role of Monoamine Oxidase Activity in Aging and Alzheimer’s Disease
    Md. Sohanur Rahman et al, 2021, Current Pharmaceutical Design CrossRef
  61. Danshensu attenuates scopolamine and amyloid-β-induced cognitive impairments through the activation of PKA-CREB signaling in mice
    Ho Jung Bae et al, 2019, Neurochemistry International CrossRef
  62. Benextramine and derivatives as novel human monoamine oxidases inhibitors: an integrated approach
    Maria Luisa Di Paolo et al, 2019, The FEBS Journal CrossRef
  63. Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine
    Dmitriy Matveychuk et al, 2021, Cellular and Molecular Neurobiology CrossRef
  64. Drugs related to monoamine oxidase activity
    Zdeněk Fišar, 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry CrossRef
  65. Platelets in Neurological Disorders
    Ilaria Canobbio et al, 2017, Platelets in Thrombotic and Non-Thrombotic Disorders CrossRef
  66. Natural Antioxidant Anthocyanins—A Hidden Therapeutic Candidate in Metabolic Disorders with Major Focus in Neurodegeneration
    Rahat Ullah et al, 2019, Nutrients CrossRef
  67. Artificial neural networks-based classification of emotions using wristband heart rate monitor data
    Yi-Chun Chen et al, 2019, Medicine CrossRef
  68. Anti-Alzheimer potential of a waste by-product (peel) of Omani pomegranate fruits: Quantification of phenolic compounds, in-vitro antioxidant, anti-cholinesterase and in-silico studies
    Rehab Khokar et al, 2021, Biocatalysis and Agricultural Biotechnology CrossRef
  69. Design, synthesis, and evaluation of 3,7-substituted coumarin derivatives as multifunctional Alzheimer’s disease agents
    Sheunopa C. Mzezewa et al, 2021, Journal of Enzyme Inhibition and Medicinal Chemistry CrossRef
  70. Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system
    Douglas L. Feinstein et al, 2016, Journal of Neurochemistry CrossRef
  71. Neuroprotective Efficacy of Apple Cider Vinegar on Zinc-High Fat Diet-Induced Mono Amine Oxidase Alteration in Murine Model of AD
    Smriti Tripathi et al, 2021, Journal of the American College of Nutrition CrossRef
  72. Membrane Reconstitution of Monoamine Oxidase Enzymes on Supported Lipid Bilayers
    Liulin Wang et al, 2018, Langmuir CrossRef
  73. Antidepressant-like effects of a new dihydro isoquinoline and its chemical precursors in mice: involvement of serotonin and dopaminergic systems
    Javier Porras-Ramírez et al, 2021, Canadian Journal of Chemistry CrossRef
  74. Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer’s Disease
    Marta Campora et al, 2021, Pharmaceuticals CrossRef
  75. Reactive Oxygen Species: Physiological and Physiopathological Effects on Synaptic Plasticity
    Thiago Fernando Beckhauser et al, 2016, Journal of Experimental Neuroscience CrossRef
  76. 8-Aminomethyl-7-hydroxy-4-methylcoumarins as Multitarget Leads for Alzheimer's Disease
    José L. Domínguez et al, 2016, ChemistrySelect CrossRef
  77. Occurrence of Morpholine in Central Nervous System Drug Discovery
    Elena Lenci et al, 2021, ACS Chemical Neuroscience CrossRef
  78. Curcumin–Coumarin Hybrid Analogues as Multitarget Agents in Neurodegenerative Disorders
    Elías Quezada et al, 2021, Molecules CrossRef
  79. Isoquinoline alkaloids from the roots of Zanthoxylum rigidum as multi-target inhibitors of cholinesterase, monoamine oxidase A and Aβ1-42 aggregation
    Erika Plazas et al, 2020, Bioorganic Chemistry CrossRef
  80. The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase
    Samantha Mostert et al, 2017, European Journal of Medicinal Chemistry CrossRef
  81. Exosomes: a novel therapeutic target for Alzheimer’s disease?
    Zhi-You Cai et al, 2018, Neural Regeneration Research CrossRef
  82. Inhibition of monoamine oxidase by benzoxathiolone analogues
    Samantha Mostert et al, 2016, Bioorganic & Medicinal Chemistry Letters CrossRef
  83. Alterations in the nigrostriatal dopamine system after acute systemic PhIP exposure
    Zeynep Sena Agim et al, 2018, Toxicology Letters CrossRef
  84. Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist with therapeutic interest in Alzheimer’s disease
    François-Xavier Toublet et al, 2021, European Journal of Medicinal Chemistry CrossRef
  85. Insights into the Mechanism of the Therapeutic Potential of Herbal Monoamine Oxidase Inhibitors in Neurological Diseases
    Ashi Mannan et al, 2021, Current Drug Targets CrossRef
  86. In silico discovery of noteworthy multi-targeted acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease
    Sabreena Chowdhury Raka et al, 2020, Advances in Traditional Medicine CrossRef
  87. Pyridazinones containing dithiocarbamoyl moieties as a new class of selective MAO-B inhibitors
    Pedro Besada et al, 2021, Bioorganic Chemistry CrossRef
  88. Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer’s Disease
    Huan Wang et al, 2019, ACS Chemical Neuroscience CrossRef
  89. Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT
    Lieven D. Declercq et al, 2016, Frontiers in Pharmacology CrossRef
  90. Optimization of the Synthesis of 18 F‐D 2 ‐Deprenyl With Mild 18 F ‐Fluorination and Minimum Precursor Input for PET Imaging of Neuroinflammation
    Sang Ju Lee et al, 2020, Bulletin of the Korean Chemical Society CrossRef
  91. Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease
    Martín Estrada Valencia et al, 2018, European Journal of Medicinal Chemistry CrossRef
  92. Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer’s disease
    Rui Xu et al, 2018, Bioorganic & Medicinal Chemistry CrossRef
  93. The Positive Modulation Effect of a 6-Week Consumption of an Anthocyanin-Rich Mulberry Milk on Working Memory, Cholinergic, and Monoaminergic Functions in Healthy Working-Age Adults
    Wipawee Thukham-mee et al, 2021, Oxidative Medicine and Cellular Longevity CrossRef
  94. Chromones: privileged scaffolds for the production of multi-target-directed-ligand agents for the treatment of Alzheimer’s disease
    Carlos F. M. Silva et al, 2018, Expert Opinion on Drug Discovery CrossRef
  95. Propargylamine-derived multi-target directed ligands for Alzheimer’s disease therapy
    Maria do Carmo Carreiras et al, 2020, Bioorganic & Medicinal Chemistry Letters CrossRef
  96. Platelets: Peripheral Biomarkers of Dementia?
    Oluwatomi E.S. Akingbade et al, 2018, Journal of Alzheimer's Disease CrossRef
  97. Tryptophan-Tyrosine Dipeptide, the Core Sequence of β-Lactolin, Improves Memory by Modulating the Dopamine System
    Yasuhisa Ano et al, 2019, Nutrients CrossRef
  98. Essential Oils as a Potential Neuroprotective Remedy for Age-Related Neurodegenerative Diseases: A Review
    Aswir Abd Rashed et al, 2021, Molecules CrossRef